IGF-1: The Growth Factor With a Longevity Paradox

What IGF-1 Is and Why It Is Measured

Insulin-like growth factor 1 is produced largely by the liver in response to growth hormone, and it mediates most of growth hormone's anabolic effects. It circulates bound to binding proteins, principally IGFBP-3, which regulate availability.

It is measured rather than growth hormone because growth hormone is secreted in pulses, so a random level is uninformative. IGF-1 integrates growth hormone exposure over roughly a day and is stable enough to measure in a single sample, which makes it the practical proxy.

Levels peak in adolescence and decline with age. Interpretation requires age-specific reference ranges, and reading an adult value against a broad range is a common error, as with DHEA-S.

Determinants include growth hormone status, nutritional state, particularly protein and total energy intake, liver function, insulin status, and genetics. Notably, IGF-1 falls with fasting and protein restriction, which is one route by which dietary interventions engage this pathway.

The Longevity Evidence for Lower

Model organisms. Reduced insulin and IGF-1 signalling is one of the most reproducible lifespan-extending manipulations across species. Mutations in the pathway extend lifespan substantially in worms, flies and mice, and growth hormone receptor knockout mice are among the longest-lived mouse strains.

Humans with growth hormone receptor deficiency. Cohorts with Laron syndrome show markedly reduced cancer and diabetes incidence, which is a striking observation, alongside short stature and other consequences.

Cancer associations. Higher IGF-1 associates with increased incidence of several cancers including prostate, breast and colorectal, in observational and Mendelian randomisation analyses. This is mechanistically coherent, since IGF-1 promotes proliferation and inhibits apoptosis.

Dietary connection. Protein restriction lowers IGF-1, and this is one proposed mechanism by which protein restriction extends lifespan in animals. It is also the point where the conflict with musculoskeletal health becomes concrete.

The Evidence for Higher, in Older Adults

The U-shaped mortality finding is the crux. Several large cohort analyses report higher mortality at both extremes, which means neither maximising nor minimising IGF-1 is supported and there is no established target.

A reasonable synthesis: high IGF-1 favours proliferation, which carries cancer risk, and low IGF-1 favours catabolism, which carries frailty risk. Which risk dominates depends on age and context, with cancer risk more relevant in midlife and frailty risk more relevant in later decades. That framing is plausible and not established.

What This Means for Protein Intake

The practical collision is over protein, and it is worth resolving explicitly because the two literatures give opposite advice.

Protein restriction lowers IGF-1 and extends lifespan in animal models. Higher protein intake raises IGF-1 and supports muscle mass, strength and bone, which predict function and mortality in older humans.

The resolution most researchers in this area propose is age-dependent. Lower protein intake may be favourable in midlife from a cancer and IGF-1 perspective, and higher protein intake is clearly favourable in later decades where sarcopenia risk dominates. Some observational work has reported exactly this pattern, with higher protein intake associated with higher mortality in middle age and lower mortality after 65.

That evidence is observational and the age cut-offs are not established, so it should be held loosely. What is firmer: in adults over 65, the evidence for adequate protein at 1.2 to 1.6 g per kg supporting muscle, bone and function is substantially stronger than the evidence that restricting protein to lower IGF-1 improves outcomes at that age.

For someone in midlife the honest answer is that the trade-off is real and unresolved, and that protein adequate for muscle maintenance rather than maximised is a defensible middle position.

Growth Hormone, and Why Not to Take It

Growth hormone administration to raise IGF-1 deserves direct comment because it is marketed and used.

In adults with genuine growth hormone deficiency, usually from pituitary disease, replacement is an established therapy with clear indications and monitoring.

In healthy older adults, the position is different. Trials of growth hormone administration report increased lean mass and reduced fat mass alongside side effects including joint pain, carpal tunnel syndrome, oedema, impaired glucose tolerance and gynaecomastia. Improvements in strength and function have generally not matched the body composition changes, which suggests the added lean mass is partly fluid.

The theoretical cancer concern follows from the IGF-1 proliferation mechanism and has not been resolved by trials, which have been too short and small to address it.

Growth hormone secretagogues and peptides marketed to raise it sit in the research-chemical category with the sourcing problems that implies, and oral amino acid combinations marketed for growth hormone release produce transient rises of no established consequence.

What raises IGF-1 without pharmacology: adequate protein and energy intake, resistance training, and adequate sleep, since growth hormone secretion is concentrated in slow-wave sleep.

How to Use the Measurement

Clinically indicated: investigating suspected growth hormone deficiency or excess, monitoring acromegaly management, and assessing growth in children. These are the established uses.

Reasonable in a longevity panel: as context, read against age-specific ranges, understanding that there is no target to move it toward.

Interpretive notes: IGF-1 falls with fasting, protein restriction, liver disease and poorly controlled diabetes, and rises with adequate nutrition and in acromegaly. Age-specific ranges are essential. Assay variation between laboratories is substantial enough that serial comparison needs the same laboratory.

What not to do: restrict protein specifically to lower IGF-1 in later life, where the musculoskeletal cost is better established than the benefit; or take growth hormone or secretagogues to raise it in the absence of a clinical indication.

Markedly abnormal values in either direction warrant clinical assessment, since pituitary disease is the relevant consideration.

The honest conclusion is that IGF-1 is among the most scientifically interesting markers in this cluster and among the least actionable, and that recognising a genuine trade-off is more useful than manufacturing a target.